These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 15019272

  • 1. Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4).
    O'Donnell JM, Zhang HT.
    Trends Pharmacol Sci; 2004 Mar; 25(3):158-63. PubMed ID: 15019272
    [No Abstract] [Full Text] [Related]

  • 2. The potential of phosphodiesterase 4 inhibitors for the treatment of depression: opportunities and challenges.
    Renau TE.
    Curr Opin Investig Drugs; 2004 Jan; 5(1):34-9. PubMed ID: 14983971
    [Abstract] [Full Text] [Related]

  • 3. Behavioural effects of selective PDE4 inhibitors in relation to inhibition of catalytic activity and competition for [3H]rolipram binding.
    Kapui Z, Bence J, Boronkay E, Mikus E, Urbán Szabó K, Baranyi A, Arányi P.
    Neurobiology (Bp); 1999 Jan; 7(1):71-3. PubMed ID: 10746252
    [No Abstract] [Full Text] [Related]

  • 4. Antidepressant-like effects of PDE4 inhibitors mediated by the high-affinity rolipram binding state (HARBS) of the phosphodiesterase-4 enzyme (PDE4) in rats.
    Zhang HT, Zhao Y, Huang Y, Deng C, Hopper AT, De Vivo M, Rose GM, O'Donnell JM.
    Psychopharmacology (Berl); 2006 Jun; 186(2):209-17. PubMed ID: 16586089
    [Abstract] [Full Text] [Related]

  • 5. Implications of PDE4 structure on inhibitor selectivity across PDE families.
    Ke H.
    Int J Impot Res; 2004 Jun; 16 Suppl 1():S24-7. PubMed ID: 15224132
    [Abstract] [Full Text] [Related]

  • 6. Analysis of the effects of phosphodiesterase type 3 and 4 inhibitors in cerebral arteries.
    Birk S, Edvinsson L, Olesen J, Kruuse C.
    Eur J Pharmacol; 2004 Apr 05; 489(1-2):93-100. PubMed ID: 15063160
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents.
    Doherty AM.
    Curr Opin Chem Biol; 1999 Aug 05; 3(4):466-73. PubMed ID: 10419856
    [Abstract] [Full Text] [Related]

  • 9. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K.
    Eur J Pharmacol; 2006 Mar 08; 533(1-3):110-7. PubMed ID: 16458289
    [Abstract] [Full Text] [Related]

  • 10. Anti-inflammatory and utero-relaxant effects in human myometrium of new generation phosphodiesterase 4 inhibitors.
    Oger S, Méhats C, Barnette MS, Ferré F, Cabrol D, Leroy MJ.
    Biol Reprod; 2004 Feb 08; 70(2):458-64. PubMed ID: 14561639
    [Abstract] [Full Text] [Related]

  • 11. Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy.
    Verhoest PR, Proulx-Lafrance C, Corman M, Chenard L, Helal CJ, Hou X, Kleiman R, Liu S, Marr E, Menniti FS, Schmidt CJ, Vanase-Frawley M, Schmidt AW, Williams RD, Nelson FR, Fonseca KR, Liras S.
    J Med Chem; 2009 Dec 24; 52(24):7946-9. PubMed ID: 19919087
    [Abstract] [Full Text] [Related]

  • 12. Effects of rolipram, a phosphodiesterase 4 inhibitor, in combination with imipramine on depressive behavior, CRE-binding activity and BDNF level in learned helplessness rats.
    Itoh T, Tokumura M, Abe K.
    Eur J Pharmacol; 2004 Sep 13; 498(1-3):135-42. PubMed ID: 15363987
    [Abstract] [Full Text] [Related]

  • 13. Discriminative stimulus effects of the type-4 phosphodiesterase inhibitor rolipram in rats.
    Makhay MM, Houslay MD, O'Donnell JM.
    Psychopharmacology (Berl); 2001 Nov 13; 158(3):297-304. PubMed ID: 11713620
    [Abstract] [Full Text] [Related]

  • 14. Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors.
    Castro A, Jerez MJ, Gil C, Martinez A.
    Med Res Rev; 2005 Mar 13; 25(2):229-44. PubMed ID: 15514991
    [Abstract] [Full Text] [Related]

  • 15. Increased building block access through collaboration.
    Helal CJ, Bartolozzi A, Goble SD, Mani NS, Guzman-Perez A, Ohri AK, Shi ZC, Subramanyam C.
    Drug Discov Today; 2018 Aug 13; 23(8):1458-1462. PubMed ID: 29571837
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Phosphodiesterase-4 as a potential drug target.
    Zhang KY, Ibrahim PN, Gillette S, Bollag G.
    Expert Opin Ther Targets; 2005 Dec 13; 9(6):1283-305. PubMed ID: 16300476
    [Abstract] [Full Text] [Related]

  • 18. Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.
    Kleinman EF, Campbell E, Giordano LA, Cohan VL, Jenkinson TH, Cheng JB, Shirley JT, Pettipher ER, Salter ED, Hibbs TA, DiCapua FM, Bordner J.
    J Med Chem; 1998 Jan 29; 41(3):266-70. PubMed ID: 9464356
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.